Vaxart Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VXRT Nasdaq 8731 https://vaxart.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vaxart Inc

Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate - Jun 6th, 2023 12:00 pm
Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET - May 31st, 2023 12:00 pm
Here's Why We're A Bit Worried About Vaxart's (NASDAQ:VXRT) Cash Burn Situation - May 31st, 2023 11:47 am
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results - May 4th, 2023 8:01 pm
Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4 - Apr 28th, 2023 12:00 pm
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge - Apr 24th, 2023 9:30 am
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6 - Mar 29th, 2023 12:00 pm
Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call Transcript - Mar 18th, 2023 6:56 am
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus - Mar 17th, 2023 12:00 pm
Vaxart Provides Business Update and Full Year 2022 Financial Results - Mar 15th, 2023 8:01 pm
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15 - Mar 8th, 2023 9:05 pm
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate - Feb 14th, 2023 1:00 pm
Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains? - Jan 9th, 2023 1:27 pm
Vaxart Names Phillip Lee as Chief Financial Officer - Dec 19th, 2022 1:00 pm
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers - Dec 1st, 2022 1:00 pm
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29 - Nov 22nd, 2022 1:30 pm
Vaxart Third Quarter 2022 Earnings: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021) - Nov 11th, 2022 10:47 am
VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates - Nov 8th, 2022 10:45 pm
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results - Nov 8th, 2022 9:01 pm
VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nov 1st, 2022 2:01 pm